TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27066336
Drug: Evolocumab self-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab self-administration
Study: 27066336
Drug: Evolocumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (both dosing schedules and devices)
Study: 27066464
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone therapy (MPT)
Study: 27067321
Drug: Pod-intravaginal ring
Normalized name: Senna pod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pod-intravaginal ring (pod-IVR) delivering a combination of TDF and MVC
Study: 27067336
Drug: Sulfamethoxazole-trimethoprim (SXT)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole-trimethoprim (SXT) administered orally at a dose of 960 mg once daily
Study: 27068396
Drug: Artesunate-Mefloquine (ASMQ)
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-Mefloquine (ASMQ) fixed-dose combination
Study: 27068662
Drug: Recruitment strategies
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment strategies including preparation, process, and patient-centeredness
Study: 27071063
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout homogenate (BSH) containing sulforaphane (SFN), dosage and duration not specified.
Study: 27071399
Drug: Proactive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive care (mailed invitation followed by telephone outreach, offer of smoking cessation services, access to pharmacotherapy)
Study: 27071922
Drug: Binimetinib 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib 45 mg BID
Study: 27071922
Drug: Binimetinib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib 30 mg BID
Study: 27071922
Drug: Binimetinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (both doses)
Study: 27072954
Drug: Transdermal latrepirdine
Normalized name: Latrepirdine
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal latrepirdine (5 mg and 10 mg for EMs)
Study: 27072954
Drug: Oral latrepirdine
Normalized name: Latrepirdine
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral latrepirdine (8.14 mg)
Study: 27074795
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) abatacept (single dose at baseline) followed by 4 weeks break and then continuation of weekly SC abatacept from day 28.
Study: 27075016
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of olaparib and irinotecan
Study: 27075906
Drug: Elevated MMA
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated MMA (>271 nmol/L)
Study: 27076600
Drug: Aldosterone Antagonist
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone Antagonist (AA)
Study: 27076600
Drug: Renin-Guided Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-Guided Therapy (RGT)
Study: 27076940
Drug: S-1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 at 60 mg/m(2)/day
Study: 27076940
Drug: S-1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 at 70 mg/m(2)/day
Study: 27076940
Drug: S-1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 at 80 mg/m(2)/day
Study: 27078728
Drug: Sunitinib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib, a small tyrosine kinase inhibitor
Study: 27078728
Drug: Bevacizumab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, a therapeutic antibody
Study: 27079334
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy with aspirin and clopidogrel after PCI
Study: 27080929
Drug: Anakinra (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (recombinant human IL-1 receptor antagonist) administered by daily subcutaneous injection for 2-6 weeks
Study: 27084282
Drug: Nurse educational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse educational oral feeding programme
Study: 27084281
Drug: Antirheumatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antirheumatic treatment (biologicals and/or conventional synthetic DMARDs)
Study: 27084534
Drug: Stage-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage-based treatment approach
Study: 27084692
Drug: Escitalopram 10-20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10-20 mg/d for 16 weeks, augmented with aripiprazole 2-10 mg/d if clinically warranted after 8 weeks
Study: 27085172
Drug: bivalent oral
Normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent oral polio vaccine (bOPV)
Study: 27087519
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg daily plus pantoprazole 40 mg twice daily for 6 months
Study: 27088859
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg/d for 8 weeks
Study: 27090116
Drug: PDA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA with injection reminder function
Study: 27090116
Drug: PDA without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDA without injection reminder function
Study: 27090917
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection at the upper inner thigh
Study: 27090917
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection at the outer thigh
Study: 27091189
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment in Korean MDD patients
Study: 27091189
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment in STAR*D level 1 (n=1677)
Study: 27091421
Drug: LFA102 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFA102 at 60 mg/kg intravenously once every 4 weeks
Study: 27091847
Drug: Surgical or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical or catheter-based treatment of VSD (5.2% of cases, 181 children)
Study: 27091847
Drug: Isolated VSDs
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated VSDs (no treatment specified)
Study: 27092197
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (dabigatran), taken twice daily (bid) according to label recommendation
Study: 27092830
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks
Study: 27093291
Drug: Intravaginal ring
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ring delivering 150 mg DL-lactic acid for 7 days
Study: 27093291
Drug: Intravaginal ring
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ring delivering 150 mg DL-lactic acid
Study: 27093365
Drug: Pembrolizumab (anti-PD-1)
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (anti-PD-1) at a dose of 2 mg/kg every 3 weeks
Study: 27094489
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral aspirin and folic acid
Study: 27095043
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine challenge dose (10μg HBs antigen)
Study: 27096100
Drug: Intranodal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranodal and intradermal backup options
Study: 27096100
Drug: Intranodal route
Normalized name: ALCOHOL 80 mL in 100 mL INTRANODAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranodal route of DC vaccines
Study: 27098749
Drug: BMX-001 (manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMX-001 (manganese porphyrin) administered subcutaneously
Study: 27099175
Drug: Nav1.7 sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nav1.7 sodium channel blocker (new potent and selective compound)
Study: 27099175
Drug: Nav1.7 blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nav1.7 blockers (including clinical test agent)
Study: 27103349
Drug: GSK2126458 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2126458 (a novel, potent PI3K/mTOR inhibitor)
Study: 27106070
Drug: Intradetrusor onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intradetrusor onabotulinumtoxinA (BoNT-ONA) injections
Study: 27106966
Drug: New score
Approvals — FDA: no, EMA: no, PMDA: no
Description: New score based on two retained STOP-BANG questions (treatment for hypertension and neck circumference >40 cm)
Study: 27108080
Drug: Accelerated hypofractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hypofractionated three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, combined with platinum doublet chemotherapy
Study: 27109549
Drug: Sunitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 15 mg/m2 orally once daily for 4 weeks every 6 weeks
Study: 27110377
Drug: Routine non-invasive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine non-invasive management with optimal medical therapy
Study: 27110385
Drug: Abatacept 125
Normalized name: abatacept 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 125 mg weekly with background methotrexate
Study: 27110385
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg bi-weekly with background methotrexate
Study: 27111235
Drug: High CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CAR-T cell doses and tumor burden
Study: 27111235
Drug: Risk-stratified CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-stratified CAR-T cell dosing based on BM disease burden
Study: 27111344
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drugs administered during follow-up)
Study: 27112607
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers use
Study: 27112607
Drug: Death or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Death or treatment withdrawal due to terminal status
Study: 27114712
Drug: SIJ fusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SIJ fusion using iFuse Implant System(®)
Study: 27115431
Drug: Abbott HCV
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbott HCV core antigen (cAg) assay with a clinical cutoff of 10 fmol/l
Study: 27116013
Drug: MLS(®) laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLS(®) laser therapy (LT) - 6 sessions, beam area 19.635 cm², 0.168 W/cm², 4 J/cm², starting at fraction 20 of radiotherapy
Study: 27116013
Drug: MLS(®) laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLS(®) laser therapy (LT)
Study: 27116183
Drug: Foretinib 60
Normalized name: Foretinib
DrugBank: Foretinib (DB12307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foretinib 60 mg po daily
Study: 27116379
Drug: Icatibant (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant (self-administered for 62.3% of attacks, healthcare professional-administered for 37.7%)
Study: 27118284
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment (Group 1)
Study: 27118540
Drug: Flavopiridol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavopiridol (30 mg/m² loading dose followed by 30 mg/m² infusion once weekly for 3 weeks every 5 weeks for 2 cycles)
Study: 27121782
Drug: SB-756050 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-756050 (various doses)
Study: 27121782
Drug: SB-756050 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-756050 (two lowest doses)
Study: 27121782
Drug: SB-756050 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-756050 (two highest doses)
Study: 27121782
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg single dose on Day 6)
Study: 29728798
Drug: Irinotecan-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan-based chemotherapy
Study: 27124184
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication usage
Study: 27124486
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg, twice daily) and trametinib (2 mg/d) continuously until disease progression or intolerance
Study: 27124486
Drug: Dabrafenib and
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib and trametinib treatment
Study: 27124835
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg daily for 21 days every 28 days)
Study: 27125892
Drug: Liletta® 52-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liletta® 52-mg IUS
Study: 27128233
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg, followed by 200 mg QD for days 2-7) plus tofacitinib (30 mg on day 5)
Study: 27128233
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg QD for days 1-3) plus tofacitinib (10 mg on day 3)
Study: 27128614
Drug: sirolimus (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus (1-4 mg daily oral maintenance doses)
Study: 27128675
Drug: Artemether-lumefantrine (days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (days 0-2) plus single dose primaquine (0.75mg/kg on day 2) for P. falciparum infections
Study: 27129117
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg single dose in subjects with mild hepatic impairment
Study: 27129117
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg single dose in subjects with moderate hepatic impairment
Study: 27129325
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy (GT) using an autologous CD34(+)-enriched cell fraction transduced with a retroviral vector encoding human ADA cDNA (GSK2696273)
Study: 27130222
Drug: blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: blood pressure augmentation
Study: 27130222
Drug: cell-based therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cell-based therapies
Study: 27133664
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 mcg b.i.d.)
Study: 27133759
Drug: Nintedanib 200mg
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib 200mg BID daily in a 4-week cycle until progression or intolerable toxicity
Study: 27135612
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (40 mg/m2 on day 1 and 8) with erlotinib (100 mg daily) in the CSV group (N = 16)
Study: 27135612
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (100 mg/week) with erlotinib (100 mg daily) in the MSV group (N = 14)
Study: 27135612
Drug: Vinorelbine co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine co-administration in the CSV group
Study: 27135612
Drug: Vinorelbine co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine co-administration in the MSV group
Study: 27136905
Drug: Migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Migalastat HCl 150 mg (single oral dose)
Study: 27136910
Drug: Oral canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral canagliflozin 300 mg
Study: 27136910
Drug: Intravenous [(14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous [(14) C]-canagliflozin 10 µg
Study: 27137149
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg once daily on days 1 and 6, twice daily on days 2-5
Study: 27137427
Drug: Escitalopram, sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, sertraline, or venlafaxine extended-release, open-label treatment for 8 weeks
Study: 27137427
Drug: Escitalopram and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram and sertraline
Study: 27138310
Drug: Non-Vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Vitamin K antagonist oral anticoagulants (NOAC)
Study: 27138628
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation at varying doses (50 to 750 mg kg(-1) day(-1))
Study: 27139036
Drug: Cixutumumab 6
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab 6 mg/kg q2w
Study: 27139036
Drug: Cixutumumab 10
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab 10 mg/kg q2w
Study: 27139036
Drug: Cixutumumab 15
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab 15 mg/kg q3w
Study: 27139036
Drug: Cixutumumab 20
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab 20 mg/kg q3w
Study: 27139473
Drug: β-lactam/β-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the empirical-therapy cohort (ETC)
Study: 27139473
Drug: Carbapenems in
Normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenems in the empirical-therapy cohort (ETC)
Study: 27139473
Drug: β-lactam/β-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the targeted-therapy cohort (TTC)
Study: 27139473
Drug: Carbapenems in
Normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenems in the targeted-therapy cohort (TTC)
Study: 27139805
Drug: Investigational trivalent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational trivalent GBS vaccine (20 μg dose, two injections, 1 month apart)
Study: 27139805
Drug: Investigational trivalent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational trivalent GBS vaccine (0.5 μg, 2.5 μg, or 5.0 μg doses, one injection at 28-35 weeks' gestation)
Study: 27139805
Drug: Investigational trivalent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational trivalent GBS vaccine (various doses)
Study: 27140229
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily with deleobuvir 800 mg twice daily (b.i.d.) and weight-based ribavirin for 24 weeks
Study: 27140229
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily with deleobuvir 600 mg three times daily (t.i.d.) and weight-based ribavirin for 24 weeks
Study: 27140401
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron infusion
Study: 27140533
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk insulin
Study: 27140533
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk leptin and insulin
Study: 27142174
Drug: Guideline-indicated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-indicated care (including dietary advice, smoking cessation advice, P2Y12 inhibitors, coronary angiography)
Study: 27142184
Drug: Autofluorescence bronchoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autofluorescence bronchoscopy (AFB) in addition to low-dose CT (LDCT) scan
Study: 27142184
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (LDCT) scan
Study: 27142472
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ASO) administered as an intravenous infusion over 1-2 hours daily for 4 days in week 1 and for 2 days in weeks 2-6 of an 8-week cycle.
Study: 27142472
Drug: Cisplatin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-sensitive SCLC.
Study: 27142472
Drug: Cisplatin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-refractory SCLC.
Study: 27142672
Drug: Hypocaloric hyperproteic
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric hyperproteic diet (HHD), ~1000 kcal/day, ~125 g protein/day for 3 weeks